Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Sug Kyun | - |
dc.contributor.author | Pack, Seung Pil | - |
dc.contributor.author | Oh, Jin-Gyo | - |
dc.contributor.author | Kang, Nam Kyu | - |
dc.contributor.author | Chang, Myung Hee | - |
dc.contributor.author | Chung, Yoon Hee | - |
dc.contributor.author | Kim, Sung-Jo | - |
dc.contributor.author | Lee, Jong Wook | - |
dc.contributor.author | Heo, Tae-Hwe | - |
dc.date.accessioned | 2021-09-07T05:22:44Z | - |
dc.date.available | 2021-09-07T05:22:44Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 1567-5769 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/110951 | - |
dc.description.abstract | Recombinant human erythropoietin (rhEPO) has been successfully used for correcting renal anemia. However, recent studies have raised some concerns about the safety of rhEPO treatment due to its immunogenic side effect pure red cell aplasia (PRCA). We now report a case of development of anti-EPO neutralizing antibodies (Abs) implicated in thrombocytopenia as well as erythrocytopenia. A 35-year-old man had a history of administering rhEPO (epoetin alfa, epoetin beta and darbepoetin alfa) for 2 years to treat renal anemia. The hematological parameters were collected. Anti-EPO, anti-platelet, and anti-thrombopoietin (TPO) Ab assays were performed to test the presence of autoreactive Abs. After performing antibody assays due to severe resistance to rhEPO treatment, a high titer of anti-EPO neutralizing Abs was detected. However, unexpectedly, this patient also showed thrombocytopenia rather than PRCA. We investigated the cause of the marked thrombocytopenia and found anti-TPO Abs in patient serum. To our best knowledge, this is the first report of the development of anti-TPO Abs during rhEPO treatment for anemia. (C) 2011 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | RED-CELL APLASIA | - |
dc.subject | THROMBOCYTOPENIA | - |
dc.subject | SITES | - |
dc.title | Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Pack, Seung Pil | - |
dc.identifier.doi | 10.1016/j.intimp.2011.10.014 | - |
dc.identifier.scopusid | 2-s2.0-81855198907 | - |
dc.identifier.wosid | 000298460700040 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL IMMUNOPHARMACOLOGY, v.11, no.12, pp.2237 - 2241 | - |
dc.relation.isPartOf | INTERNATIONAL IMMUNOPHARMACOLOGY | - |
dc.citation.title | INTERNATIONAL IMMUNOPHARMACOLOGY | - |
dc.citation.volume | 11 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2237 | - |
dc.citation.endPage | 2241 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | RED-CELL APLASIA | - |
dc.subject.keywordPlus | THROMBOCYTOPENIA | - |
dc.subject.keywordPlus | SITES | - |
dc.subject.keywordAuthor | Erythrocytopenia | - |
dc.subject.keywordAuthor | Pure red cell aplasia | - |
dc.subject.keywordAuthor | Erythropoietin | - |
dc.subject.keywordAuthor | Thrombocytopenia | - |
dc.subject.keywordAuthor | Thrombopoietin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.